RxDoctor Payments Data

Michael Talone, OD

Optometrist · State College, PANPI 1023006202

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (34.2%), education and food and beverage — rather than concentrated in one kind of arrangement. Coopervision Inc. accounts for 70.6% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2019 at $6,027 and has fallen 96.0% since, to $244 in 2025. Among optometrist clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$13,968in general payments, 2019–2025

Across 101 payments — averaging $138.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coopervision Inc.$10K
  • Biotissue Holdings Inc.$2K
  • Lombart Brothers, Inc.$500
  • Topcon Healthcare, Inc.$458
  • Bausch & Lomb Americas Inc.$311
  • Johnson & Johnson Vision Care, Inc.$179
  • plus $978 from 11 others

What the payments were for

  • Speaking & faculty fees$4,78134%
  • Travel & lodging$1,34710%
  • Food & beverage$3,33324%
  • Education$4,50832%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,968 in reported general payments places this provider in the 95th percentile of 2,165 optometrist providers in Pennsylvania.

See all optometrist providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$32,571
Medicare patients
174
Services billed
430

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost46$15,774
XiidraLifitegrast13$9,939
VyzultaLatanoprostene Bunod26$6,961
Loteprednol Etabonate13$2,358
Latanoprost113$1,330
Timolol Maleate28$1,004
Prednisolone Acetate23$745
MoxifloxacinMoxifloxacin Hcl11$171

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$311$16,90139 claims
AbbVieLumigan$158$15,77446 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$133$2,35813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,165 optometrist providers in Pennsylvania.

Other optometrist in State College

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →